TY - JOUR T1 - Chondroitin sulfate is superior to placebo in symptomatic knee osteoarthritis JF - Annals of the Rheumatic Diseases JO - Ann Rheum Dis DO - 10.1136/annrheumdis-2017-212452 SP - annrheumdis-2017-212452 AU - Young Ho Lee Y1 - 2017/10/09 UR - http://ard.bmj.com/content/early/2017/10/08/annrheumdis-2017-212452.abstract N2 - I read with great interest the article by Reginster and colleagues1 regarding the effectiveness of chondroitin sulfate (CS) in the treatment of symptomatic knee osteoarthritis (OA). This randomised, double-blind trial demonstrated that pharmaceutical-grade CS is superior to placebo and equivalent to celecoxib in reducing pain and improving function over 6 months in patients with symptomatic knee OA, indicating that this formulation of CS should be considered a first-line treatment in the … ER -